UBC Researchers Achieve Breakthrough in Stem Cell Immunotherapy

Researchers at the University of British Columbia have achieved a significant breakthrough in stem cell engineering by successfully producing human immune cells known as helper T cells from stem cells in a controlled laboratory environment. This discovery, published in the journal Cell Stem Cell, addresses a longstanding challenge that has hindered the development and manufacturing of effective cell therapies.

The ability to generate helper T cells reliably could transform the landscape of treatments for various conditions, including cancer, infectious diseases, and autoimmune disorders. “Engineered cell therapies are transforming modern medicine,” stated Dr. Peter Zandstra, co-senior author and director of the UBC School of Biomedical Engineering. He emphasized that this study offers a scalable method to produce multiple types of immune cells, making advanced therapies more accessible.

Addressing the Challenges of Living Drugs

In recent years, engineered cell therapies, particularly CAR-T treatments, have shown remarkable success in treating patients with previously untreatable cancers. These therapies involve reprogramming immune cells to identify and combat diseases. Despite their potential, the high costs and complex production processes have limited their availability. Currently, most treatments require the use of a patient’s own immune cells, extending the manufacturing timeline to weeks.

The research team aims to create off-the-shelf therapies that can be prepared in advance from renewable sources like stem cells. “This would make treatments more cost-effective and readily available when patients need them,” said Dr. Megan Levings, co-senior author and professor of surgery and biomedical engineering at UBC.

For effective cancer treatment, it is crucial to have both killer T cells, which directly attack infected or malignant cells, and helper T cells, which coordinate the immune response. While progress has been made in generating killer T cells, the production of helper T cells has remained elusive until now. “Helper T cells are essential for a strong and lasting immune response,” Dr. Levings noted. “Having both types maximizes the effectiveness of therapies.”

Breakthrough in Controlled Development

In their study, the UBC researchers tackled the challenge of producing helper T cells by manipulating biological signals during cell development. They identified that a signaling pathway called Notch plays a critical role in determining whether stem cells develop into helper or killer T cells. The timing and intensity of this signal were key factors; if Notch remains active for too long, it hinders the formation of helper T cells.

“By precisely tuning when and how much this signal is reduced, we were able to direct stem cells to become either helper or killer T cells,” explained Dr. Ross Jones, co-first author and research associate in the Zandstra Lab. The team conducted their experiments under controlled conditions that can be applied to real-world biomanufacturing, progressing toward viable therapies.

Remarkably, the lab-produced helper T cells displayed characteristics of mature immune cells, including a diverse array of immune receptors and the ability to differentiate into subtypes essential for immune function. “These cells look and act like genuine human helper T cells,” said Kevin Salim, a UBC PhD student involved in the research. This quality is crucial for their potential therapeutic applications.

The researchers assert that the ability to produce both helper and killer T cells, along with controlling their balance, will enhance the efficacy of future stem cell-based immune therapies. “This is a major step forward in developing scalable and affordable immune cell therapies,” Dr. Zandstra concluded. “This technology lays the groundwork for exploring how helper T cells can support cancer elimination and facilitate the creation of new cell types, such as regulatory T cells, for clinical use.”

As this research progresses, it holds promise for revolutionizing how cell therapies are manufactured and administered, potentially improving patient outcomes worldwide.